Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 2
1993 1
1994 1
1995 4
1996 1
1997 3
1998 3
1999 4
2000 4
2001 9
2002 9
2003 11
2004 11
2005 9
2006 11
2007 20
2008 22
2009 9
2010 19
2011 26
2012 27
2013 29
2014 22
2015 23
2016 18
2017 18
2018 11
2019 13
2020 17
2021 21
2022 17
2023 19
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

373 results

Results by year

Filters applied: . Clear all
Page 1
Primary central nervous system lymphoma.
Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L, Ponzoni M, Batchelor TT. Ferreri AJM, et al. Nat Rev Dis Primers. 2023 Jun 15;9(1):29. doi: 10.1038/s41572-023-00439-0. Nat Rev Dis Primers. 2023. PMID: 37322012 Review.
Chronic lymphocytic leukaemia.
Scarfò L, Ferreri AJ, Ghia P. Scarfò L, et al. Among authors: ferreri aj. Crit Rev Oncol Hematol. 2016 Aug;104:169-82. doi: 10.1016/j.critrevonc.2016.06.003. Epub 2016 Jun 16. Crit Rev Oncol Hematol. 2016. PMID: 27370174 Review.
CNS prophylaxis for diffuse large B-cell lymphoma.
Eyre TA, Savage KJ, Cheah CY, El-Galaly TC, Lewis KL, McKay P, Wilson MR, Evens AM, Bobillo S, Villa D, Maurer MJ, Cwynarski K, Ferreri AJM. Eyre TA, et al. Among authors: ferreri ajm. Lancet Oncol. 2022 Sep;23(9):e416-e426. doi: 10.1016/S1470-2045(22)00371-0. Lancet Oncol. 2022. PMID: 36055310 Review.
How we treat primary central nervous system lymphoma.
Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM. Calimeri T, et al. Among authors: ferreri ajm. ESMO Open. 2021 Aug;6(4):100213. doi: 10.1016/j.esmoop.2021.100213. Epub 2021 Jul 13. ESMO Open. 2021. PMID: 34271311 Free PMC article. Review.
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Fowler NH, et al. Among authors: ferreri ajm. Nat Med. 2022 Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17. Nat Med. 2022. PMID: 34921238 Free article. Clinical Trial.
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Martelli M, et al. Among authors: ferreri aj. Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71. doi: 10.1016/j.critrevonc.2012.12.009. Epub 2013 Jan 30. Crit Rev Oncol Hematol. 2013. PMID: 23375551 Review.
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, Hottinger AF, Kasenda B, Lefranc F, Lossos A, McBain C, Preusser M, Roth P, Rudà R, Schlegel U, Soffietti R, Soussain C, Taphoorn MJB, Touitou V, Weller M, Bromberg JEC. Hoang-Xuan K, et al. Among authors: ferreri ajm. Neuro Oncol. 2023 Jan 5;25(1):37-53. doi: 10.1093/neuonc/noac196. Neuro Oncol. 2023. PMID: 35953526 Free PMC article.
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6. Lancet Haematol. 2016. PMID: 27132696 Clinical Trial.
373 results